XML 16 R4.htm IDEA: XBRL DOCUMENT v3.25.2
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Revenues:        
Total revenue $ 966,630 $ 385,896 $ 1,360,202 $ 720,513
Costs and expenses:        
Costs of research and development revenue 148,457 301,956 274,937 445,911
Costs of grant revenue 465,134 636,312
Research and development 629,379 515,629 1,124,358 1,038,352
General and administrative 1,436,630 1,607,756 3,032,968 3,396,350
Foreign currency exchange loss 16,098 3,146 23,170 8,049
Total costs and expenses 2,695,698 2,428,487 5,091,745 4,888,662
Loss from operations (1,729,068) (2,042,591) (3,731,543) (4,168,149)
Other income (expense):        
Interest income 49,127 138,471 137,585 225,914
Gain on sale of Alphazyme 60,977
Total other income (expense), net (64,706) (2,632) (89,810) 113,330
Net loss $ (1,793,774) $ (2,045,223) $ (3,821,353) $ (4,054,819)
Basic net loss per common share $ (0.06) $ (0.07) $ (0.13) $ (0.14)
Diluted net loss per common share $ (0.06) $ (0.07) $ (0.13) $ (0.14)
Basic weighted-average common shares outstanding 30,102,324 29,291,259 30,071,285 29,085,696
Diluted weighted-average common shares outstanding 30,102,324 29,291,259 30,071,285 29,085,696
Nonrelated Party [Member]        
Other income (expense):        
Interest expense $ (89,456) $ (88,634) $ (178,699) $ (110,273)
Related Party [Member]        
Other income (expense):        
Interest expense (24,377) (52,469) (48,696) (63,288)
Research and Development [Member]        
Revenues:        
Total revenue 213,449 385,896 396,549 720,513
Grant [Member]        
Revenues:        
Total revenue 503,181 713,653
License [Member]        
Revenues:        
Total revenue $ 250,000 $ 250,000